capecitabine / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

678 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
capecitabine / Generic mfg.
NCT06023758: Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC

Recruiting
2
18
RoW
KN026, KN046, XELOX
Peking University
HER2-positive Locally Advanced Resectable Gastric Cancer
09/25
12/26
SIROCHO, NCT05265208: Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Suspended
2
62
Europe
Capecitabine, L01BC06, Selective Internal Radiotherapy (SIRT), Surgery
Center Eugene Marquis
Resectable Intrahepatic Cholangiocarcinoma
09/27
02/30
IMPROVE, NCT06120127: Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence

Recruiting
2
80
RoW
SBRT, radiotherapy, Chemotherapy, PD-1 antibody, Sintilimab
Fudan University
Radiotherapy, Immunotherapy, Liver Metastases, Colorectal Cancer
09/25
09/25
DESTINY-Gastric03, NCT04379596: Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer

Jul 2023 - Dec 2023: Data from DESTINY-Gastric03 trial for gastric cancer
Checkmark Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Jul 2020 - Jul 2020: Presentation of data from DESTINY-Gastric03 study in HER2-overexpressing gastric cancer at ESMO 2020
Recruiting
2
413
Europe, Canada, Japan, US, RoW
Fluorouracil (5-FU), Capecitabine, Durvalumab, MEDI4736, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, DS-8201a, Cisplatin, Pembrolizumab, Volrustomig, MEDI5752, Rilvegostomig, AZD2936
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Gastric Cancer
07/26
07/26
GEMINI-Gastric, NCT05702229 / 2022-002840-29: Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting
2
240
Europe, Japan, US, RoW
Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD7789, AZD0901, 5-Fluorouracil, Capecitabine
AstraZeneca, AstraZeneca AB
Gastric Cancer
09/25
03/26
CAIRO7, NCT05092880: Radioembolization in Elderly/ Fragile Patients With mCRC

Recruiting
2
220
Europe
radioembolization, Standard of care first-line systemic therapy
UMC Utrecht, Dutch Colorectal Cancer Group
Colorectal Cancer Metastatic
10/25
10/28
NCT05563012: Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma

Recruiting
2
29
RoW
Sintilimal Injection, Capecitabine, Oxaliplatin
Renmin Hospital of Wuhan University
Disorder in Complete Remission in Response to Treatment
10/25
10/26
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients

Recruiting
2
477
Europe
5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib
Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc.
Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer
10/25
12/27
NCT06016387: Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD

Recruiting
2
30
Canada
Tucatinib 150 MG, Tukysa, Trastuzumab, Capecitabine, Brain & Spinal Radiation, Brain & Spinal XRT
Sunnybrook Health Sciences Centre, Seagen Inc., Biocon Biologics
HER2-positive Breast Cancer, LMD
10/25
10/28
FISSION, NCT06091423: XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Recruiting
2
43
RoW
XELOX combined with Fruquintinib and Sintilimab
Xiaofeng Chen
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
11/25
11/26
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
11/25
10/26
NCT03396926: Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

Completed
2
44
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Capecitabine, Ro 09-1978/000, Xeloda, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
University of California, San Francisco, Merck Sharp & Dohme LLC
Microsatellite Stable, Mismatch Repair Protein Proficient, Stage III Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
01/24
01/24
RAXO, NCT01531595 / 2011-003137-33: Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer

Recruiting
2
100
Europe
Bevacizumab plus alternating Xelox/Xeliri, Avastin, Xeloda, irinotecan, oxaliplatin
Pia Osterlund
Metastatic Colorectal Cancer
12/25
12/25
PaTK02, NCT02446093: Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active, not recruiting
2
54
US, RoW
Aglatimagene besadenovec, CAN-2409, AdV-tk, Chemoradiation, Stereotactic body radiation therapy, Surgery
Candel Therapeutics, Inc., Mayo Clinic
Borderline Resectable Pancreatic Adenocarcinoma
12/25
07/26
NCT02688712: ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Active, not recruiting
2
50
US
LY2157299, Galunisertib, Capecitabine, Xeloda, Fluorouracil, 5-fluorouracil , 5-FU, Adrucil, Efudex, Fluoroplex, Tumor specific mesorectal excision
Providence Health & Services, Eli Lilly and Company
Rectal Adenocarcinoma
12/25
12/25
NCT04753879: Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Recruiting
2
38
US
Nab-paclitaxel, Gemcitabine, Cisplatin, Irinotecan, Capecitabine, Pembrolizumab, Olaparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC
Metastatic Pancreatic Cancer
12/25
12/29
BCTOP-L-M05, NCT05594095: SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
2
140
RoW
PIK3CA inhibitor, AKT inhibitor, Carrelizumab, SHR1210, Famitinib, Fluzoparib, SHR3162, Dalpiciclib, SHR6390, SHR-A1811, TROP2 ADC, Everolimus, Aromatase Inhibitors or Fulvestrant, Goserelin, TPC, RTK Inhibitor
Fudan University, Peking University Cancer Hospital & Institute, First Hospital of China Medical University, Sun Yat-sen University, First Affiliated Hospital Xi'an Jiaotong University, Chongqing University Cancer Hospital, Northern Jiangsu People's Hospital, Fujian Medical University Union Hospital, Ningbo Medical Center Lihuili Hospital, Shanghai First Maternity and Infant Hospital, Shanghai 6th People's Hospital, Affiliated Hospital of Nantong University
Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
12/25
12/26
NCT05659290: Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Recruiting
2
40
RoW
Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus Capecitabine
Nanfang Hospital of Southern Medical University
Metastatic Colorectal Cancer
12/25
12/25
NCT05468138: PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Not yet recruiting
2
141
RoW
SOX, XELOX, Observation, PD-1 antibody
Fudan University
MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
12/25
12/25
NCT05515796: Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Recruiting
2
200
RoW
Terelizumab (aka Tislelizumab), CapeOx, Trastuzumab, Radiotherapy
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Immunotherapy, Gastric Cancer, Rectal Cancer, Chemotherapy Effect, Radiotherapy
12/25
12/25
Miracle-G, NCT06121700: Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Recruiting
2
55
RoW
Radiotherapy targeted to the primary lesion, Radiotherapy targeted to the metastatic lesions, Anti-PD-1 monoclonal antibody, Trastuzumab, Herceptin®, Chemotherapy, R0 total/subtotal gastrectomy with D2 lymphadenectomy, Metastasectomy, Local ablative therapies
Fudan University
Adenocarcinoma, Stomach Neoplasm, Gastroesophageal-junction Cancer, Oligometastatic Disease, Metastatic Cancer, Metastatic Gastric Cancer, Adenocarcinoma of the Stomach, Gastroesophageal Junction Adenocarcinoma, Metastatic Adenocarcinoma
12/25
12/27
NCT05833672: Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers

Not yet recruiting
2
100
RoW
Terelizumab, CapeOx
fan li
Colon Cancer, Immunotherapy
12/25
12/25
NCT06118658: Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Not yet recruiting
2
30
RoW
tislelizumab
China Medical University, China
Gastric, Colorectal Adenocarcinoma
12/25
12/26
NCT05975749: Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer

Recruiting
2
114
RoW
Serplulimab, Trastuzuma, Chemotherapy
Fudan University
Gastric Cancer
01/26
01/29
LOGICAN, NCT05476796: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
NCT04768426: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Recruiting
2
25
US
Capecitabine, fluoropyrimidine carbamate
Stanford University
Triple Negative Breast Cancer, Breast Cancer
02/26
02/26
NCT05062317: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases

Recruiting
2
120
US
Leucovorin, Citrovorum, Wellcovorin®, 5-FLUOROURACIL, Oxaliplatin, Eloxatin, Irinotecan, Capecitabine, Xeloda, Bevacizumab, Avastin™, Anti-VEGF monoclonal antibody, rhuMAb-VEGF
M.D. Anderson Cancer Center
Liver Metastases
02/26
02/26
NCT05929885: Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

Recruiting
2
50
RoW
Low Dose OXIRI (LD-OXIRI)
National Cancer Centre, Singapore, National Medical Research Council (NMRC), Singapore
Metastatic Pancreatic Cancer
02/26
02/26
NCT05720559: Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Not yet recruiting
2
100
NA
Oxaliplatin, S1, Cetuximab, Metronidazole, Vitamin A, Folic acid, Capecitabine
Liaoning Tumor Hospital & Institute
Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
03/26
09/26
AMBITION, NCT05939661: A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer

Recruiting
2
45
Japan
Radiation, Chemotherapy, Surgery
Osaka University
Rectal Cancer
03/26
03/30
NCT06084897: Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Recruiting
2
120
RoW
TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice., Chemotherapy, PD-1 inhibitor, Immunotherapy, Consolidation Radiation, Planned Radiotherapy, Salvage Radiation, Radiotherapy when needed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Hebei Medical University Fourth Hospital, Tianjin Medical University Cancer Institute and Hospital, Anyang Tumor Hospital
Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb
04/26
10/28
NCT05851924: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Recruiting
2
60
US
NALIRIFOX, AD-XRT and Capecitabine
Memorial Sloan Kettering Cancer Center, Ipsen, Pancreatic Cancer Research Fund
Pancreatic Ductal Adenocarcinoma
05/26
05/26
ChiCTR2300073467: PD-1 inhibitor combined with nimotuzumab and gemcitabine plus cisplatin for the first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma: a single arm, phase II clinical study

Recruiting
2
26
China
The first stage is the PD-1 inhibitor plus nimotuzumab and chemotherapy combination treatment, 21 days is a cycle, a total of 4-6 cycles, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion, day 0 (one day before chemotherapy); Nimotuzumab, intravenous infusion, on day 0 (one day before chemotherapy); Chemotherapy: Gemcitabine, intravenous infusion, day 1 and 8, (1000mg/m2), Cisplatin, intravenous infusion, day 1 (80mg/ m2). The second stage is the maintenance treatment, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion (day 1, every 3 weeks); Capecitabine (650mg/m2, take orally, two times every day); PD-1 inhibitor and Capecitabine should be administered until the end of the study.
Dongguan People's Hospital ; Dongguan People's Hospital, Biotech Pharmaceutical Co., Ltd
nasopharyngeal carcinoma
 
 
NCT04443543: An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

Not yet recruiting
2
222
RoW
Capecitabine (Xeloda) Pharmacogenetic Test Reagents, irinotecan, IMRT, Oxaliplatin, 5Fluorouracil, Tislelizumab
Fudan University
Rectal Cancer
06/26
12/26
NCT05628922: Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Recruiting
2
198
RoW
Toripalimab, JS001, Induction chemotherapy and concurrent chemoradiation
Fudan University
Nasopharyngeal Cancer
07/26
07/27
NCT05861271: Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Recruiting
2
1008
RoW
Capecitabine，Pyrotinib, Pyrotinib
Fudan University
Breast Cancer Stage I
07/26
07/28
NCT05671822: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2+ Gastric Cancer

Recruiting
2
156
RoW
SHR-A1811；SHR-1701；capecitabine；oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HER2+ Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
07/26
07/26
NCT05826964: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Recruiting
2
500
US
AI+CDK4/6i, Aromatase Inhibitor (AI) + Cyclin dependent kinase 4 and 6 inhibitor (CDK4/6i), Anastrozole, Letrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib, SERD+CDK4/6i, Selective Estrogen Receptor Degrader (SERD) + CDK4/6i, Fulvestrant, mTOR inhibitor + AI, Mammalian target of rapamycin (mTOR) inhibitor + Aromatase Inhibitor (AI), Everolimus, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, Tamoxifen, PI3K inhibitor + SERD, Phosphoinositide 3-kinase (PI3K) inhibitor + SERD, Alpelisib, PI3K inhibitor + AI, Chemotherapy, Taxane, Eribulin, Capecitabine, Vinorelbine, Oral SERD, Elacestrant
University of Miami
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
07/26
07/29
NCT05514275: Radiotherapy Combined With Endostatin and Capecitabine for NPC

Recruiting
2
41
RoW
Endostatin and Capecitabine
Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
08/26
08/28
NCT05870800: Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Not yet recruiting
2
30
US
Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Neoadjuvant Chemoimmunotherapy, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, mFOLFOX6, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2, CAPEOX
Baylor College of Medicine, Genentech, Inc.
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
09/26
01/28
NCT05679583: Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer

Recruiting
2
25
RoW
Preoperative Stereotactic body radiation therapy (SBRT), Pancreatic resection, Adjuvant Chemotherapy
Yonsei University
Pancreatic Cancer
09/26
09/26
NCT05292742: Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Recruiting
2
206
RoW
Pyrotinib+Trastuzumab+Capecitabine, Trastuzumab+Pertuzumab/Trastuzumab
Fujian Medical University Union Hospital
Breast Cancer, Adjuvant Therapy
10/26
12/27
NCT06094868: Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer

Not yet recruiting
2
45
NA
Fruquintinib, Sintilimab, Oxaliplatin, Capecitabine
Second Affiliated Hospital of Nanchang University
Gastric Cancer
10/26
10/26
B2019-149, NCT04304209: Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

Active, not recruiting
2
195
RoW
Oxaliplatin, Capecitabine, Sintilimab, radiotherapy, total mesorectal excision, Watch and wait
Sun Yat-sen University
Colorectal Cancer Stage II, Colorectal Cancer Stage III
10/26
10/26
ChiCTR2000039242: Palbociclib plus aromatase inhibitor/fulvestrant with ovarian function suppression versus docetaxel plus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative local recurrent or metastatic breast cancer: a multicentre, prospective, randomised, non-inferiority, phase 2 trial

Recruiting
2
174
 
palbociclib plus aromatase inhibitor/fulvestrant with ovarian function suppression ;docetaxel plus capecitabine and sequential capecitabine
The Second Affiliated Hospital of Dalian Medical University; The Second Affiliated Hospital of Dalian Medical University, Self-financing
Breast Cancer
 
 
ETIC-LM, NCT05800275: Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Recruiting
2
30
Europe
Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection
UNICANCER, Seagen Inc.
Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer
12/26
06/27
NCT04165772: Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Recruiting
2
200
US
TSR-042 or Dostarlimab, Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
Memorial Sloan Kettering Cancer Center, Tesaro, Inc.
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
11/26
11/26
NCT06070740: First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Recruiting
2
22
RoW
Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
Peking Union Medical College Hospital
Gastrointestinal Neuroendocrine Carcinoma
11/26
12/26
NCT06124378: Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Recruiting
2
60
RoW
Tislelizumab, Tevimbra, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Colectomy, Surgery
First Affiliated Hospital of Guangxi Medical University
Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
11/26
11/26
TUC-TOC, NCT05955170: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Recruiting
2
66
Europe
Tucatinib in Combination of Oral VP16 and trastuzumab
Institut Curie, Seagen Inc.
HER2-positive Breast Cancer
12/26
12/27
NCT05290194: Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

Recruiting
2
28
RoW
SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1 inhibitor, Immune Checkpoint Inhibitors, Capecitabine, Xeloda
Fifth Affiliated Hospital, Sun Yat-Sen University
Radiotherapy, PD-1 Inhibitor, Capecitabine, Nasopharyngeal Carcinoma
12/26
01/27
NCT03161522: Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

Recruiting
2
100
US
Capecitabine, Ro 09-1978/000, Xeloda, Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Conventional Surgery, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7
12/26
12/26
NCT04566380: ONO-4538 Phase II Rollover Study (ONO-4538-98)

Recruiting
2
59
Japan, RoW
ONO-4538, oxaliplatin, S-1, capecitabine, bevacizumab, temozolomide
Ono Pharmaceutical Co. Ltd
Pan-tumor
12/26
12/26
HERCKER-01, NCT05985707: KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Not yet recruiting
2
80
RoW
KN026, KN046, XELOX
Peking University Cancer Hospital & Institute
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer
12/26
12/26
NCT05998122: Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study

Not yet recruiting
2
45
RoW
nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
The First Hospital of Jilin University
Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
12/26
12/28
NCT06110598: CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

Not yet recruiting
2
86
US
Capecitabine, Xeloda®
Lee Ocuin, MD
Pancreas Cancer, Pancreas Adenocarcinoma
12/26
12/27
ChiCTR2200056870: An open, multicenter, single-arm, phase II study evaluating triplimumab injection (JS001) combined with chemotherapy for neoadjuvant treatment of gastric/gastroesophageal junction cancer

Not yet recruiting
2
40
China
Toripalimab injection (JS001) combined with capecitabine and oxaliplatin
Guangdong Provincial People's Hospital ; Guangdong Provincial People's Hospital, Tririplizumab injection (JS001) was provided free of charge by Shanghai Junshi Biomedical Technology Co., LTD.
gastric/gastroesophageal junction carcinoma
 
 
KEYVIBE-005, NCT05007106 / 2021-001009-56: MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005)

Recruiting
2
610
Europe, Canada, Japan, US, RoW
Pembrolizumab/Vibostolimab Co-Formulation, MK-7684A, Pembrolizumab, MK-3475, KEYTRUDA®, Lenvatinib, Lenvima, E7080, MK-7902, 5-Fluorouracil, 5-FU, Fluracil, Cisplatin, Platinol, cis Platinum, Paclitaxel, Taxol, Abraxane, Anzatax, Gemcitabine, Carboplatin, Docetaxel, Bevacizumab, Capecitabine, Oxaliplatin
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms, Cholangiocarcinoma, Esophageal Neoplasms, Triple Negative Breast Neoplasms, Hepatocellular Carcinoma, Urinary Bladder Neoplasms, Ovarian Neoplasms, Stomach Neoplasms
02/27
02/27
AK104-IIT-13, NCT05794750: Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（）

Not yet recruiting
2
50
NA
AK104 injection, Immunotherapy, TME surgery, Surgery, Capecitabine, Chemotherapy drug, Oxaliplatin
JIN JING
Locally Advanced Rectal Cancer
04/27
04/27
NCT05228431: Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer

Recruiting
2
121
RoW
XELOX, Capecitabine monotherapy, Radiation
Zhen-Hai Lu
Advanced Rectal Cancer
05/27
05/28
ORIENTA, NCT06102824: Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting
2
252
RoW
Organoid-guided treatment, Taxane, Abraxane, Lipusu, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine, Eribulin, Halaven, Anthracycline, Doxil, Lipodox, Carboplatin, Paraplatin, Utidelone, UTD1, Trastuzumab deruxtecan, Enhertu, Sacituzumab govitecan, Trodelvy
Guangdong Provincial People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-sen University, Shantou Central Hospital
HER2-negative Breast Cancer, Advanced Breast Cancer
06/27
06/28
Apollo, NCT04501523: A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC

Recruiting
2
460
RoW
Tislelizumab, capecitabine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple-negative Breast Cancer
08/27
08/32
ChiCTR2200062900: Carrelizumab combined with GP induction chemotherapy, cisplatin concurrent chemoradiotherapy, and capecitabine adjuvant chemotherapy for high-risk locally advanced nasopharyngeal carcinoma: a prospective, single-arm, open, single-center, phase II trial

Recruiting
2
49
 
Carrelizumab combined with GP induction chemotherapy, cisplatin concurrent chemoradiotherapy and capecitabine adjuvant chemotherapy
Affiliated Cancer Hospital&Institute of Guangzhou Medical University; Guangzhou Medical University Affiliated Cancer Center, No funding
Nasopharyngeal Carcinoma
 
 
INSIGHT, NCT05693766: Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

Recruiting
2
64
US
Capecitabine, Endocrine-therapy, MammoPrint ® and BluePrint assays
Sonya Reid, Agendia, Susan G. Komen Breast Cancer Foundation
Invasive Mammary Carcinoma, Metastatic Breast Cancer
08/27
08/37
NCT05484375: Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Not yet recruiting
2
40
NA
Capecitabine plus toripalimab
Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Hunan Cancer Hospital
Metastatic Nasopharyngeal Carcinoma
09/27
09/29
MRIMR-1, NCT05359393: A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

Not yet recruiting
2
52
RoW
a combination therapy including tislelizumab, preoperative radiotherapy combined with immunotherapy and chemotherapy
Fudan University
Advanced Rectal Cancer, Liver Metastasis, Pulmonary Metastasis, Microsatellite Stable Colorectal Carcinoma
09/27
09/27
TBCRC 058, NCT06099769: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
2
201
US
Enzalutamide, Mifepristone, TPC
Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc., Breast Cancer Research Foundation, Corcept Therapeutics
Metastatic Breast Cancer
10/27
10/27
NCT05836584: Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Recruiting
2
240
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Lymphadenectomy, excision of the lymph node, Lymph Node Dissection, Lymph Node Excision, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI)
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/27
10/27
WW3, NCT04095299: Standard Dose Versus High Dose of Radiotherapy in Rectal Preservation With Chemo-radiotherapy in Rectal Cancer Patients

Recruiting
2
111
Europe
50.4 Gy to the tumor and elective volume, 62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume, Capecitabine 825 mg/m2 twice daily on weekdays
Vejle Hospital
Cancer of Rectum
12/27
12/28
TRACE-LE, NCT05969847: Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer

Not yet recruiting
2
72
RoW
split-course hypofraction radiotherapy, hypofraction radiotherapy, CAPOX, Capecitabine+Oxaliplatin, Envafolimab, KN035, Local excision
池畔
Rectal Cancer
12/27
12/27
NCT05247905: Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Recruiting
2
198
US
Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
03/28
10/33
ChiCTR2300070798: Conversion therapy of Sintilimab combined with Lenvatinib and XELOX (oxaliplatin and capecitabine) chemotherapy in primary unresectable gastric cancer

Not yet recruiting
2
34
 
Sintilimab combined with Lenvatinib and XELOX (oxaliplatin and capecitabine) chemotherapy
JiangSu province hospital; JiangSu province hospital, self-financing
gastric cancer
 
 
SIRIUS, NCT05375708: Systemic Therapy in Combination With Stereotactic Radiotherapy in Patients With Metastatic Colorectal Cancer up to 10 Metastatic Sites

Not yet recruiting
2
93
Europe
Stereotactic body radiation therapy (SBRT), Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
UMC Utrecht
Metastatic Colorectal Cancer, Oligometastatic Disease
06/28
06/28
NCT05526079: Watchful Waiting for Complete Responders to Therapy in Rectal Cancer

Recruiting
2
30
US
Watchfuf waiting
Ascension South East Michigan
Rectal Cancer
07/28
07/29
NCT06093061: Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

Not yet recruiting
2
69
RoW
CCRT with Maintenance Tislelizumab and Metronomic Capecitabine
National Cancer Centre, Singapore, BeiGene, Tan Tock Seng Hospital
Nasopharyngeal Carcinoma
10/28
10/29
BETTER 2, NCT03351296: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting
2
140
Europe
LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pancreatic Cancer
12/28
12/28
NCT06105684: Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

Not yet recruiting
2
40
US
Capecitabine Pill, Xeloda
University of Alabama at Birmingham
Metastatic Breast Cancer
01/28
01/28
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
NCT04929028: Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Recruiting
2
53
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Mitomycin, Ametycine, Jelmyto, MITO, Mito-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
National Cancer Institute (NCI)
AIDS-Related Anal Carcinoma, Anal Basaloid Squamous Cell Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
09/29
09/29
NCT04166318: Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Recruiting
2
252
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Mitomycin, Ametycine, MITO, MITO-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
12/29
12/29
NCT02491697: Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer

Active, not recruiting
2
400
RoW
DC-CIK Immunotherapy, DC-CIK, Capecitabine Monotherapy, Capecitabine
The First People's Hospital of Changzhou
Breast Cancer
08/30
08/33
BRE-08, NCT06085742: Phase II Study of CMC Regimen for Early Stage Breast Cancer

Recruiting
2
25
US
Cyclophosphamide, Methotrexate, Capecitabine
University of Illinois at Chicago
Breast Cancer
09/34
09/34
NCT02598349: Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

Recruiting
2
60
US
Proton Radiation, Proton Beam Radiation, Capecitabine, Xeloda, Surgical resection
Proton Collaborative Group, University of Florida Health
Pancreatic Cancer
10/39
10/40
VOLTAGE, NCT02948348: Study to Nivolumab Following Preoperative Chemoradiotherapy

Recruiting
1b/2
90
Japan
Nivolumab, Opdivo, Chemoradiotherapy with capecitabine, Surgical therapy, Ipilimumab, Yervoy
Takayuki Yoshino, Ono Pharmaceutical Co. Ltd
Cancer of Rectum
12/21
08/22
QUILT-3.071, NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Active, not recruiting
1b/2
332
US
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
ImmunityBio, Inc.
Colorectal Cancer Metastatic, mCRC
12/22
12/22
NCT05990543: Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Not yet recruiting
1b/2
59
NA
Nelmastobart and Capecitabine
Korea University Anam Hospital
Recurrent or Metastatic Colorectal Cancer
10/25
03/26
CAPRICE, NCT05519670: A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr

Not yet recruiting
1b/2
72
NA
Niraparib Oral Product
Institut Paoli-Calmettes, GlaxoSmithKline
Breast Cancer
09/27
12/27
ACTRN12617001268336: Direct Isolation Chemotherapy to Supplement Systemic Intravenous Chemotherapy for those with Liver Metastases from Colorectal Cancer

Recruiting
1/2
95
 
AllVascular Pty Ltd, NSW Health Medical Device Fund
Liver Cancer
 
 
2006-003085-34: A Dose-escalating, Multicenter, Single arm, Open-label Study of XRP6258 in combination with capecitabine (Xeloda®), in patients with metastatic breast cancer with disease progressing after anthracycline and taxane therapy

Ongoing
1/2
50
Europe
XRP6258, Concentrate for solution for infusion, Film-coated tablet, Xeloda
sanofi-aventis recherche & developpement
Metastatic Breast Cancer
 
 
2009-010093-38: Multi-institutional Phase I/II Study: Neoadjuvant chemoradiation with 5-FU (or capecitabine) and oxaliplatin combined with deep regional hyperthermia in locally advanced or recurrent rectal cancer

Ongoing
1/2
110
Europe
Capecitabine, Oxaliplatin, Solution for infusion, Film-coated tablet, Concentrate for solution for infusion
Dekan of the Medical Faculty of the University Erlangen-Nuremberg; Prof. Dr. Dr. h. c. Jürgen Schüttler, Strahlenklinik Erlangen
Locally advanced primary or locally recurrent rectal cancer, Locally advanced primary or locally recurrent rectal cancer, Diseases [C] - Digestive System Diseases [C06]
 
 
ChiCTR-ONC-12002387: Clinical study of changing dose fractionation patterns of preoperative intensity-modulated radiotherapy (IMRT) in locally advanced rectal cancer

Completed
1/2
20
 
Patients will received capecitabine (825 mg/m2, bid d1-5 weekly) and SIB-IMRT delivering 58.75 Gy/25F (2.35Gy/fraction) to the gross tumor and regional transforming lymph nodes while simultaneously delivering 50Gy/25F (2.0 Gy/fraction) to the areas at high risk for harboring microscopic disease. ;One cycle of capecitabine (1250 mg/m2, twice daily, d1-14) was given one week after the completion of chemoradiation(CRT), and total mesorectal excision was scheduled 6 to 8 weeks after the completion of CRT. Five cycle of adjuvant chemotherapy based on 5-FU was given after the completion of survery.
Chinese PLA General Hospital; Level of the institution：, Chinese PLA General Hospital
Rectal cancer
 
 
2004-000602-44: Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado

Ongoing
1/2
63
Europe
Navelbine cápsulas blandas, Xeloda, NA, Navebine Cápsulas Blandas, Xeloda 500, 100 mg, Navebine Cápsulas Blandas, Xeloda 500, 100 mg
Pierre Fabre Ibérica, S.A.
Advanced breast cancer (metastatic)
 
 
2005-002801-22: Carboplatin Plus Xeloda Followed By Maintenance Xeloda (CARBOX)

Ongoing
1/2
20
Europe
Capecitabine, Carboplatin, Capecitabine, Carboplatin, Capecitabine, Carboplatin
The Royal Marsden NHSF Trust
relapsed ovarian cancer
 
 
2006-002389-21: A phase I/II study of Docetaxel (Taxotere, TM), Cisplatinum and Capecitabine (Xeloda, TM) (TCX) in patients with advanced oesophago-gastric cancer.

Ongoing
1/2
80
Europe
Docetaxel, Cisplatin, Capecitabine, Not applicable, Taxotere, Cisplatin, Xeloda, Taxotere, Cisplatin, Xeloda
North Wales NHS Trust
Locally advanced or metastatic adenocarcinoma, squamous cell carcinoma or undifferentiated carcinoma of the oesophagus, oesophago-gastric junction or stomach.
 
 
2006-000081-36: Ensayo en Fase I-II para evaluar la administración de radioterapia concomitante prequirúrgica y quimioterapia con satraplatin más capecitabina en el tratamiento del adenocarcinoma rectal localmente avanzado

Ongoing
1/2
20
Europe
Satraplatino, JM-216, Xeloda, Xeloda
GPC Biotech AG
Adenocarcinoma rectal localmente avanzado
 
 
2008-001662-85: Phase 1/2 Randomized, Open-label, Three Arm Study of Neratinib (HKI-272) vs. Neratinib + Capecitabine vs. Lapatinib + Capecitabine, in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or locally advanced Breast Cancer

Ongoing
1/2
40
Europe
neratinib, HKI-272, XELODA 150 mg comprimidos recubiertos con película, TYVERB 250 mg comprimidos recubiertos con película, XELODA 150 mg comprimidos recubiertos con película, TYVERB 250 mg comprimidos recubiertos con película
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Solid tumors (part 1) and metastatic breast cancer (part 2)
 
 
2008-007686-24: A phase I/ II, non-randomized, feasibility/ safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with metastatic pancreatic cancer

Ongoing
1/2
35
Europe
certican, capecitabine, cetuximab, SE/H/356/03, EMEA/H/C/316, EMEA/H/C/558,
patients with metatastatic pancreatic cancer
 
 
ChiCTR-TRC-13003064: A Phase II Trial of QYHJ Granules Versus Xeloda in Second Line Therapy of Metastatic Pancreatic Cancer

Completed
1/2
60
 
QYHJ Granules ;Xeloda
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, no
pancreatic cancer
 
 
ChiCTR-IIR-16007947: The Study of Neoadjuvant Sandwich Treatment with XELOX Induction Chemotherapy and 5-Fu based Radiotherapy for Locally Advanced Rectal Cancer

Recruiting
1/2
80
 
5-Fu based Radiotherapy ;XELOX induction chemotherapy and 5-Fu based radiotherapy
Shanghai ChangZheng Hospital; Shanghai ChangZheng Hospital, self-collected funds
Rectal Cancer
 
 
NCT02736500: Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors

Active, not recruiting
1/2
37
Europe
28 GBq 177Lu-DOTATATE, 22 GBq 177Lu-DOTATATE
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Istituto Europeo di Oncologia IEO MILANO
Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors
04/17
06/21
 

Download Options